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Abstract
Nicotinic	acid	(NA)	activates	hydroxycarboxylic	acid	receptor	2	(HCA2),	and	it	is	widely	
used	in	treating	dyslipidaemias.	Since	its	side	effects	include	skin	dryness,	whereas	
its	deficiency	can	be	accompanied	by	dyssebacia,	characterized	by	sebaceous	gland	
enlargement,	we	asked	if	HCA2	 is	expressed	on	human	sebocytes,	and	if	NA	influ‐
ences	sebocyte	functions.	By	using	human	immortalized	SZ95	sebocytes,	we	found	
that	non‐cytotoxic	 (≤100	μmol/L;	MTT‐assay)	 concentrations	of	NA	had	no	effect	
on	the	homeostatic	sebaceous	lipogenesis	(SLG;	Nile	Red),	but	normalized	excessive,	
acne‐mimicking	SLG	induced	by	several	lipogenic	agents	(arachidonic	acid,	ananda‐
mide,	linoleic	acid	+	testosterone;	Nile	Red;	48‐hr	treatments).	Moreover,	it	exerted	
significant	anti‐proliferative	actions	(CyQUANT‐assay),	and	increased	[Ca2+]IC	(Fluo‐4	
AM‐based	Ca2+‐measurement).	Although	NA	did	not	prevent	the	lipopolysaccharide‐
induced	pro‐inflammatory	 response	 (up‐regulation	 [Q‐PCR]	 and	 release	 [ELISA]	of	
several	pro‐inflammatory	cytokines)	of	the	sebocytes,	collectively,	these	data	sup‐
port	the	concept	that	NA	may	be	effective	in	suppressing	sebum	production	in	vivo.	
While	exploring	the	mechanism	of	the	sebostatic	actions,	we	found	that	sebocytes	
express	HCA2	 (Q‐PCR,	 immunofluorescent	 labelling),	 siRNA‐mediated	 silencing	 of	
which	prevented	the	NA‐induced	Ca2+‐signal	and	the	lipostatic	action.	Collectively,	
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1  | INTRODUC TION
Acne	 is	 one	 of	 the	most	 common	 human	 skin	 diseases.	 It	 impairs	
quality	of	life	of	millions	of	patients	world‐wide,	and	is	characterized	
by	 excessively	 increased	 and	 qualitatively	 altered	 sebaceous	 lipo‐
genesis	(SLG),	complex	inflammatory	processes,	as	well	as	abnormal	
skin—microbiota	 cross‐talk.1‐4	 Although	 highly	 efficient	 anti‐acne	
agents	 (eg	 isotretinoin)	 exist,	 their	 administration	 is	 often	 limited	
by	different	(sometimes	quite	serious)	side	effects.1,2	Thus,	there	is	
an	unmet	need	from	both	the	scientific	community	and	society	to	
develop	novel,	highly	efficient	therapeutic	agents	exhibiting	better	
side	effect	and	safety	profiles.
Nicotinic	 acid	 (NA)	 and	 nicotinamide	 are	 members	 of	 the	 vi‐
tamin	 B3	 complex,	 whose	 deficiency	 leads	 to	 pellagra,	 a	 disease	
classically	characterized	by	diarrhoea,	dementia,	dermatitis,	and,	 if	
remains	untreated,	death.	 Interestingly,	 in	 light‐exposed	skin	areas	
with	high	levels	of	sebum	excretion,	such	as	the	face,	dyssebacia	(a	
sebaceous	gland	[SG]	dysfunction	characterized	by	abnormal,	inspis‐
sated	sebum	production,	as	well	as	consequently	enlarged	facial	SGs	
and	dilated	SG	orifices	through	which	the	plugs	may	be	projected)	
has	also	been	reported.5‐7	Importantly,	in	pharmacological	doses,	NA	
has	widely	been	used	in	the	clinical	practice	in	treating	dyslipidae‐
mias	for	decades,	while,	quite	surprisingly,	nicotinamide	(albeit	being	
equipotent	with	NA	as	a	vitamin)	fails	to	improve	these	conditions.8,9 
Interestingly,	clinical	administration	of	NA	is	 limited	by	a	harmless,	
but	quite	inconvenient	and	frequently	occurring	side	effect,	namely	
the	NA‐induced	 skin	 flush	 response,	which	 consists	 of	 cutaneous	
vasodilation	accompanied	by	itch	and	a	burning	sensation	mainly	af‐
fecting	the	face	and	the	upper	body.	Importantly,	we	have	previously	
demonstrated	that	the	flush	is	mediated	via	the	NA‐induced	activa‐
tion	of	hydroxycarboxylic	acid	receptor	2	(HCA2;	previously	known	
as	“HM74A”,	“niacin	receptor	1”,	“GPR109A”	or	in	mice	as	“PUMA‐G”)	
expressed	by	epidermal	Langerhans	cells.10,11
HCA2	 is	a	Gi‐coupled	 receptor	abundantly	expressed	 in	adipo‐
cytes	and	in	various	immune	cells,	where	it	is	involved	in	orchestrat‐
ing	anti‐inflammatory	actions.12‐15	Interestingly,	in	a	striking	contrast	
with	NA,	nicotinamide	has	only	negligible	 affinity	 to	HCA2,	which	
explains	its	aforementioned	inefficiency	in	the	clinical	management	
of	dyslipidaemias.9,16,17
Importantly,	 when	 applied	 at	 pharmacological	 doses,	 side	 ef‐
fects	 of	 NA	 include	 skin	 dryness	 (https	://www.drugs.com/pro/
niacin.html),	whereas	NA	deficiency	can	be	accompanied	by	seba‐
ceous	gland	enlargement.6	Moreover,	pilot	 clinical	 studies	demon‐
strate	that	high	doses	of	orally	administered	NA	may	exert	beneficial	
effects	against	acne.18‐20	Thus,	based	on	the	aforementioned	data,	
we	 hypothesized	 that	 NA	 may	 directly	 impact	 on	 the	 biology	 of	
human	 sebocytes,	 and	 that	 these	 actions	 might	 be	 mediated	 via	
HCA2	receptors.
In	order	to	challenge	this	working	hypothesis,	we	tested	effects	
of	NA,	and	putative	expression	of	HCA2.	Specifically,	we	asked	if	NA	
influences	(a)	basal	(homeostatic)	SLG;	(b)	acne	mimicking,	excessive	
SLG;	(c)	proliferation;	and	(d)	immune	behaviour	of	cultured	human	
sebocytes.	Moreover,	we	aimed	to	assess	expression	of	HCA2	and	its	
putative	role	in	mediating	the	above	actions.	Considering	the	regret‐
table	limitations	of	the	available	model	systems	to	study	sebaceous	
gland	biology,	 including	ineffective	culturing	of	primary	human	se‐
bocytes	and	 the	 lack	of	 adequate	animal	model	 systems,3,21,22 we 
decided	to	use	the	human	immortalized	SZ95	sebocyte	cell	line,22,23 
a	 widely	 accepted	 and	 reliable	 model	 to	 study	 human	 sebaceous	
gland	biology	in	vitro.2,3,22,23
2  | MATERIAL S AND METHODS
2.1 | Materials
Anandamide	 (AEA)	 and	 arachidonic	 acid	 (AA)	 were	 purchased	
from	 Cayman	 Chemical	 Company	 (Ann	 Arbor,	 MI,	 USA);	 γ‐ir‐
radiated	 lipopolysaccharide	 from	 Escherichia coli	 026:B6	 (LPS),	
linoleic	acid	(LA),	ruthenium	red	(RR),	testosterone	(T)	and	nico‐
tinic	acid	(NA)	were	obtained	from	Sigma‐Aldrich	(St.	Louis,	MO,	
USA),	whereas	BAPTA	AM	was	acquired	from	Tocris	(Bio‐Techne;	
Minneapolis,	MN,	USA).	AEA,	AA	and	LA	were	dissolved	 in	ab‐
solute	 ethanol,	 whereas	 the	 solvent	 for	 BAPTA	 AM,	 T	 and	 RR	
was	dimethyl	sulphoxide	 (DMSO).	LPS	was	dissolved	 in	 filtered	
distilled	water,	whereas	NA	was	 diluted	 directly	 in	 the	 culture	
medium.
2.2 | Cell culturing
Human	 immortalized	 SZ95	 sebocytes,	 originated	 from	 human	
facial	 sebaceous	 glands,23	 were	 cultured	 as	 described	 previ‐
ously.24,25	 Briefly,	 Sebomed®	 Basal	 Medium	 (Biochrom,	 Berlin,	
Germany)	was	supplemented	with	10	(V/V)%	fetal	bovine	serum	
(Life	 Technologies	 Hungary	 Ltd,	 Budapest,	 Hungary),	 1	 mmol/L	
CaCl2,	 5	 ng/ml	 human	 epidermal	 growth	 factor	 (Sigma‐Aldrich)	
and	MycoZap™	Plus‐CL	 (1:500;	 Lonza,	Budapest,	Hungary).	 The	
medium	was	changed	every	other	day,	and	cells	were	subcultured	
at	60%‐70%	confluence.
our	data	 introduce	NA,	and	HCA2	activators	 in	general,	as	novel,	potent	and	most	
likely	safe	sebostatic	agents,	with	possible	anti‐acne	potential.
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2.3 | Determination of intracellular lipids
For	 quantitative	 measurement	 of	 sebaceous	 (neutral)	 lipid	 con‐
tent,	cells	 (20	000	cells/well)	were	cultured	in	96‐well	“black	well/
clear	bottom”	plates	(Greiner	Bio‐One,	Frickenhausen,	Germany)	in	
quadruplicates,	and	were	treated	with	compounds	as	indicated.24‐26 
Subsequently,	 supernatants	 were	 discarded,	 cells	 were	 washed	
twice	 with	 phosphate‐buffered	 saline	 (PBS;	 115	 mmol/L	 NaCl,	
20 mmol/L Na2HPO4,	pH	7.4;	all	from	Sigma‐Aldrich),	and	100	µl	of	a	
1	µg/ml	Nile	Red	(Sigma‐Aldrich)	solution	in	PBS	was	added	to	each	
well.	The	plates	were	 then	 incubated	at	37°C	 for	30	minutes,	and	
fluorescence	was	measured	on	FlexStation	3	multimode	microplate	
reader	(Molecular	Devices,	San	Francisco,	CA,	USA).	Results,	meas‐
ured	in	relative	fluorescence	units,	are	expressed	as	percentage	of	
the	vehicle	control	regarded	as	100%,	using	485	nm	excitation	and	
565	nm	emission	wavelengths.
2.4 | Determination of cellular viability
The	viability	of	the	cells	was	determined	by	MTT‐assay	(Sigma‐Aldrich)	
measuring	the	conversion	of	the	tetrazolium	salt	to	formazan	by	mi‐
tochondrial	dehydrogenases.24‐28	Cells	were	plated	 in	96‐well	plates	
(20	000	cells/well)	 in	quadruplicates,	and	were	 treated	as	 indicated.	
Cells	were	then	incubated	with	0.5	mg/ml	MTT	reagent	for	3	hours,	and	
concentration	of	formazan	crystals	(as	an	indicator	of	number	of	viable	
cells)	was	determined	colorimetrically	at	565	nm	by	using	FlexStation	
3	multi‐mode	microplate	reader	(Molecular	Devices).	Results	were	ex‐
pressed	as	percentage	of	vehicle	control	regarded	as	100%.
2.5 | Determination of apoptosis
A	decrease	 in	 the	mitochondrial	membrane	potential	 is	one	of	 the	
earliest	markers	of	apoptosis.	Therefore,	to	assess	the	process,	mi‐
tochondrial	membrane	potential	of	SZ95	sebocytes	was	determined	
using	a	MitoProbe™	DilC1(5)	Assay	Kit	 (Life	Technologies	Hungary	
Ltd.).	24‐26	Cells	 (20	000	cells/well)	were	cultured	 in	96‐well	 “black	
well/clear	 bottom”	 plates	 (Greiner	 Bio	One)	 in	 quadruplicates	 and	
were	treated	as	indicated.	After	removal	of	supernatants,	cells	were	
incubated	for	30	minutes	with	DilC1(5)	working	solution	(50	μl/well),	
then	washed	with	PBS,	and	the	fluorescence	of	DilC1(5)	was	meas‐
ured	at	630	nm	excitation	and	670	nm	emission	wavelengths	using	
FlexStation	 3	 multi‐mode	 microplate	 reader	 (Molecular	 Devices).	
Relative	 fluorescence	values	were	expressed	as	percentage	of	ve‐
hicle	control	regarded	as	100%.	As	a	positive	control	for	apoptosis,	
we	applied	carbonyl	cyanide	m‐chlorophenyl	hydrazone	(CCCP;	Life	
Technologies	Hungary	Ltd.)	dissolved	 in	the	DilC1(5)	working	solu‐
tion	(1:200	for	30	minutes	at	37°C).
2.6 | Determination of necrosis
Necrotic	processes	were	determined	by	SYTOX	Green	staining	(Life	
Technologies	Hungary	Ltd.).24‐26	The	dye	 is	able	 to	penetrate	 (and	
then	to	bind	to	the	nucleic	acids)	only	to	necrotic	cells	with	ruptured	
plasma	membranes,	whereas	healthy	cells	with	intact	surface	mem‐
branes	show	negligible	SYTOX	Green	staining	intensity.	Cells	were	
cultured	in	96‐well	“black	well/clear	bottom”	plates	(Greiner	Bio	One),	
and	treated	as	indicated.	Supernatants	were	then	discarded,	and	the	
cells	were	 incubated	 for	30	minutes	with	1	μmol/L	SYTOX	Green	
dye.	Following	incubation,	cells	were	washed	with	PBS,	the	culture	
medium	was	replaced,	and	fluorescence	of	SYTOX	Green	was	meas‐
ured	at	490	nm	excitation	and	520	nm	emission	wavelengths	using	
FlexStation	3	multi‐mode	microplate	reader	(Molecular	Devices).	As	
a	positive	control	for	necrosis,	lysis	buffer	(LB;	1:100	in	the	SYTOX	
Green	working	solution	 for	30	minutes	at	37°C;	Life	Technologies	
Hungary	 Ltd.)	 was	 applied.	 Relative	 fluorescence	 values	 were	 ex‐
pressed	as	percentage	of	positive	control	regarded	as	100%.	Due	to	
their	spectral	properties,	DilC1(5)	and	SYTOX	Green	dyes	were	al‐
ways	administered	together,	enabling	us	to	investigate	necrotic	and	
early	apoptotic	processes	of	the	same	cultures.	Selective	decrease	
of	DilC1(5)	 intensity	 indicated	mitochondrial	 depolarization	 (ie	 the	
onset	 of	 early	 apoptotic	 processes),	 whereas	 increase	 of	 SYTOX	
Green	staining	intensity	revealed	necrotic	cell	death.
2.7 | Determination of cellular proliferation
The	 degree	 of	 cellular	 growth	 (reflecting	 proliferation)	was	 deter‐
mined	by	measuring	the	DNA	content	of	cells	using	CyQUANT	Cell	
Proliferation	Assay	Kit	(Life	Technologies	Hungary	Ltd).24,26,27	SZ95	
sebocytes	 (2000	 cells/well)	 were	 cultured	 in	 96‐well	 “black	 well/
clear	 bottom”	 plates	 (Greiner	 Bio‐One)	 and	 were	 treated	 as	 indi‐
cated.	Supernatants	were	then	removed	by	blotting	on	paper	tow‐
els,	and	the	plates	were	subsequently	 frozen	at	−80°C.	The	plates	
were	then	thawed	at	 room	temperature,	and	200	µl	of	CyQUANT	
dye/cell	lysis	buffer	mixture	was	added	to	each	well.	After	5	minutes	
of	incubation,	fluorescence	was	measured	at	490	nm	excitation	and	
520	nm	emission	wavelengths	using	FlexStation	3	multimode	micro‐
plate	reader	(Molecular	Devices).	Relative	fluorescence	values	were	
expressed	as	percentage	of	24‐hr	vehicle	control	regarded	as	100%.
2.8 | RNA isolation, reverse transcription and 
quantitative ‘real‐time’ PCR (Q‐PCR)
Q‐PCR	was	performed	on	a	Roche	LightCycler	480	System	(Roche,	
Basel,	Switzerland)	using	 the	5′	nuclease	assay.25,29	Total	RNA	was	
isolated	using	TRIzol	(Life	Technologies	Hungary	Ltd.),	DNase	treat‐
ment	 was	 performed	 according	 to	 the	 manufacturer's	 protocol,	
and	 then,	 1	 µg	 of	 total	 RNA	 was	 reverse‐transcribed	 into	 cDNA	
using	 High‐Capacity	 cDNA	 Kit	 from	 Life	 Technologies	 Hungary	
Ltd.	 PCR	 amplification	 was	 performed	 using	 the	 TaqMan® Gene 
Expression	Assays	(assay	IDs:	Hs00174092_m1	for	interleukin [IL]‐1α,	
Hs00174097_m1	 for	 IL‐1β,	Hs00985639_m1	 for	 IL‐6,	Hs00174103_
m1	 for	 IL‐8,	 Hs00174128_m1	 for	 tumour necrosis factor [TNF]‐α; 
Hs00271958_s1	for	HCA2)	and	the	TaqMan	universal	PCR	master	mix	
protocol	(Applied	Biosystems).	As	internal	controls,	transcripts	of	18S 
RNA	(assay	ID:	Hs03928985_g1)	or	glyceraldehyde 3‐phosphate dehy‐
drogenase	(GAPDH;	assay	ID:	Hs99999901_s1)	were	determined.	The	
4  |     MARKOVICS et Al.
amount	of	the	transcripts	was	normalized	to	those	of	the	housekeep‐
ing	gene	using	the	ΔCT	method.	Finally,	when	indicated,	the	relative	
expression	values	were	further	normalized	to	the	ones	of	the	vehi‐
cle‐treated	or	scrambled	RNA‐transfected	controls	(ΔΔCT	method).
2.9 | Determination of cytokine release (ELISA)
Cells	were	seeded	in	35	mm	culture	dishes	(500	000	cells/1.5	ml	me‐
dium/	dish),	and	were	treated	as	indicated	for	3	or	24	hours.24,25,29 
Supernatants	were	collected,	and	the	released	amount	of	 IL‐6	and	
IL‐8	cytokines	was	determined	using	OptEIA	kits	 (BD	Pharmingen,	
Franklin	Lakes,	NJ,	USA)	according	to	the	manufacturer's	protocol.
2.10 | Fluorescent Ca2+ measurements
Human	 SZ95	 sebocytes	 were	 seeded	 in	 96‐well	 “black	 well/clear	
bottom”	plates	(Greiner	Bio‐One)	at	a	density	of	20	000	cells/well	re‐
sulting	in	an	almost	confluent	culture,	and	treatments	were	initiated	
in	the	subsequent	day.26	The	cells	were	washed	once	with	1%	bovine	
serum	albumin	and	2.5	mmol/L	probenecid	(both	from	Sigma‐Aldrich)	
containing	 Hank's	 solution	 (136.8	 mmol/L	 NaCl,	 5.4	 mmol/L	 KCl,	
0.34 mmol/L Na2HPO4,	0.44	mmol/L	KH2PO4,	0.81	mmol/L	MgSO4,	
1.26	mmol/L	CaCl2,	5.56	mmol/L	glucose,	4.17	mM	NaHCO3,	pH	7.2,	
all	from	Sigma‐Aldrich),	and	then	were	loaded	with	1	μmol/L	Fluo‐4	
AM	 (Life	 Technologies	 Hungary	 Ltd.)	 dissolved	 in	 Hank's	 solution	
(100	μl/well)	 at	 37°C	 for	 30	minutes.	 The	 cells	were	 then	washed	
three	 times	 with	 Hank's	 solution	 (100	 μl/well).	 In	 the	 case	 of	 the	
measurements	performed	in	“Low	[Ca2+]EC”,	CaCl2	was	omitted	from	
the	 buffer,	 and	 was	 substituted	 by	 equimolar	 glucose.	 The	 plates	
were	then	placed	into	a	FlexStation	3	multi‐mode	microplate	reader	
(Molecular	 Devices),	 and	 alterations	 of	 the	 cytoplasmic	 Ca2+ con‐
centration	(reflected	by	changes	 in	fluorescence;	λEX:	490	nm,	λEM: 
520	 nm)	 were	 monitored	 following	 the	 application	 of	 compounds	
in	the	indicated	concentrations.	In	order	to	probe	reactivity	and	vi‐
ability	of	the	cells,	at	the	end	of	each	measurement,	0.2	mg/ml	ATP	
was	 administered	 as	 a	 positive	 control	 (data	 not	 shown).	Data	 are	
presented	as	F/F0,	where	F0	is	the	average	baseline	fluorescence	(ie	
before	compound	application),	whereas	F	is	the	actual	fluorescence.
2.11 | siRNA transfection‐mediated selective 
gene silencing
Human	SZ95	cells	were	seeded	in	(d	=	35	mm)	Petri	dishes	or	in	96‐well	
“black	well/clear	bottom”	plates	(Greiner	Bio‐One)	or	on	glass	coverslips	in	
6‐well	plates	in	culture	medium.	On	the	other	day,	medium	was	changed,	
and	 the	 cells	were	 transfected	with	 siRNA	oligonucleotides	 targeting	
human	HCA2	 (Stealth	 RNAi,	 assay	 ID:	 HSS155269;	 Life	 Technologies	
Hungary	Ltd.)	 using	Lipofectamine®	RNAi	MAX	Transfection	Reagent	
and	serum‐free	Opti‐MEM™	(both	from	Life	Technologies	Hungary	Ltd.).	
For	controls,	siRNA	Negative	Control	Duplexes	with	medium	GC	ratio	
(SCR,	 Life	 Technologies	Hungary	 Ltd.)	 were	 employed.	 Silencing	 effi‐
ciency	was	monitored	on	post‐transfection	Days	2	and	3	at	the	mRNA	
(Q‐PCR)	and	protein	(immunofluorescent	labelling)	levels.
2.12 | Immunofluorescent labelling
Human	 SZ95	 sebocytes	were	 cultured	 on	 glass	 coverslips	 in	 6‐well	
plates.	Cells	were	fixed	by	4%	paraformaldehyde	containing	PBS	for	
5	 minutes	 at	 room	 temperature.	 Following	 appropriate	 washing	 in	
PBS,	 coverslips	were	 incubated	 for	 30	minutes	 in	 blocking	 solution	
(3	 [V/V]%	bovine	 serum	 albumin	 containing	 PBS;	 both	 from	Sigma‐
Aldrich)	at	room	temperature.	Following	appropriate	washing	in	PBS,	
cells	were	probed	with	primary	antibodies	raised	against	human	HCA2 
(dissolved	 in	 1:50	 in	 1.5	 [V/V]%	 BSA	 containing	 PBS,	 Santa	 Cruz	
Biotechnology,	Inc,	Dallas,	TX,	USA)	for	60	minutes	at	room	tempera‐
ture.	Following	appropriate	washing	in	PBS,	coverslips	were	incubated	
with	Alexa‐Fluor®‐488‐conjugated	anti‐rabbit	IgG	Fc	segment‐specific	
secondary	antibodies	(1:1000	in	1.5	[V/V]%	BSA	containing	PBS;	Cell	
Signaling	 Technology,	 Leiden,	 The	 Netherlands)	 and	 DAPI	 (1:1000,	
Vector	 Laboratories,	 Burlingame,	 CA,	 USA)	 diluted	 together	 in	 1.5	
(V/V)%	BSA	containing	PBS	 for	1	hour	at	 room	 temperature,	which	
was	followed	by	appropriate	washing	in	PBS.	As	negative	controls,	the	
primary	 antibodies	 were	 omitted	 from	 the	 procedure.	 Visualization	
of	the	proteins	was	performed	by	using	an	Olympus	IX81	fluorescent	
microscope	 (Olympus,	 Sindzsuku,	 Tokyo,	 Japan).	 When	 indicated,	
images	were	 then	subjected	 to	 subsequent	 image	analysis	 to	assess	
semi‐quantitative	alterations	in	HCA2	expression.	In	these	cases,	im‐
ages	(taken	from	simultaneously	performed	stainings)	were	analysed	
by Fiji	software,30	and	mean	grey	values	(detected	in	the	green	channel	
by	using	strictly	the	same	settings	during	image	exposure	in	all	cases)	
were	compared	to	each	other	following	the	subtraction	of	the	back‐
ground	(ie	mean	grey	value	of	the	cell‐free	area).
2.13 | Statistical analysis
Data	 were	 analysed	 by	 IBM SPSS Statics software version 20	 (IBM	
Armonk,	 North	 Castle,	 NY,	 USA),	 using	 Student's	 two‐tailed,	
two‐sample	 t	 test	 (paired	 comparisons)	 or	 one‐way	 ANOVA	 with	
Bonferroni's	post hoc	test	(multiple	comparisons),	and	P	<	0.05	val‐
ues	were	 regarded	as	significant	differences.	Graphs	were	plotted	
using	Origin Pro Plus 6	software	(Microcal,	Northampton,	MA,	USA).
2.14 | Ethical approval
Data	presented	in	the	current	manuscript	were	generated	by	using	a	
human	immortalized	cell	line.	Since	primary	human	material	or	ani‐
mals	were	not	used,	ethical	approval	was	not	required	for	the	study.
3  | RESULTS
3.1 | Up to 100 μmol/L, NA does not decrease the 
viability of human sebocytes
First,	by	using	MTT‐assay,	we	found	that	up	to	100	µmol/L	NA	did	
not	 decrease	 the	 viability	 of	 sebocytes	 (24‐72	 hours;	 Figure	 S1).	
In	 order	 to	 exclude	 the	 possibility	 of	 the	 onset	 of	 early	 apoptotic	
and	 necrotic	 processes	 resulting	 in	 no	 obvious	 alterations	 in	 the	
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MTT‐assay,	we	further	assessed	the	effects	of	NA	by	combined	flu‐
orescent	labelling	(DilC1(5)	&	SYTOX	Green	dyes),	a	routinely	used	
method	in	our	recent	sebocyte‐oriented	studies.24‐26,31	Importantly,	
we	found	that	in	line	with	our	MTT	data,	NA	did	not	induce	apoptotic	
or	necrotic	events	(≤100	μmol/L;	24‐	and	48‐hr	treatments;	Figure	
S2),	 confirming	 that	 in	 this	 time	window	and	concentration	 range,	
it	 can	 indeed	 be	 administered	without	 the	 risk	 of	 any	 biologically	
relevant	cytotoxic	actions.
3.2 | NA does not influence homeostatic SLG, 
but normalizes various lipogenic agent‐induced, 
excessive, acne‐mimicking lipid synthesis
Next,	 by	 using	 fluorescent	 Nile	 Red	 staining,	 we	 aimed	 to	 study	
the	effects	of	NA	on	the	most	characteristic	biological	function	of	
the	sebocytes,	ie	the	basal,	homeostatic	SLG.	We	found	that,	when	
administered	 at	 the	 above‐determined	 non‐cytotoxic	 concentra‐
tions,	NA	did	not	influence	basal	SLG	in	course	of	48‐hr	treatments	
(Figure	1A).
Since	one	of	the	most	obvious	steps	of	the	pathogenesis	of	acne	
is	 seborrhea,1‐3	next	we	asked	 if	NA	 influences	pro‐acne	agent‐in‐
duced,	excessive,	acne‐mimicking	SLG.	To	test	this,	we	administered	
arachidonic	acid	(AA),	a	pro‐inflammatory	lipid	mediator	involved	in	
the	pathogenesis	of	acne,1‐4	which	promotes	SLG	mostly	via	activat‐
ing	protein	kinase	C	δ.32	As	expected,	AA	(50	μmol/L)	was	able	to	
induce	a	marked	elevation	in	the	SLG	over	the	course	of	48‐hr	treat‐
ments.	This	lipogenic	effect	was	significantly	suppressed	by	all	the	
above‐determined	non‐cytotoxic	concentrations	of	NA	with	similar	
efficiency	(Figure	1B),	indicating	that	NA	may	be	efficient	in	normal‐
izing	excessive	SLG	in	acne.
To	assess	if	this	lipogenesis‐reducing	activity	is	specific	for	AA,	
or	 if	 it	 rather	 reflects	 activation	of	 a	universal	 lipostatic	 signalling	
pathway,	 we	 probed	 NA’s	 efficiency	 against	 such	 stimuli,	 which	
are	 known	 to	 activate	 partially	 independent	 lipogenic	 signalling	
pathways.	 To	 this	 end,	 the	 endocannabinoid	 anandamide	 (AEA;	
30 μmol/L),33‐35	 an	 endogenous	 lipid	 mediator,	 which	 was	 shown	
to	promote	SLG	via	activating	CB2	cannabinoid	receptor,
31	and	the	
combination	 of	 linoleic	 acid	 and	 testosterone	 (LA	 +	 T	 in	 100	 and	
1 μmol/L,	respectively)	targeting	peroxisome	proliferator‐activated	
receptors	 (PPARs)36	 were	 applied.	 Of	 great	 importance,	 NA	 sup‐
pressed	both	lipogenic	stimuli,	irrespective	of	the	underlying	signal‐
ling	pathways	 (Figure	S3A‐B),	 supporting	 the	concept	 that	NA	 is	a	
universally	effective	 lipostatic	 agent	 (ie	 it	 can	normalize	excessive	
SLG	irrespective	of	the	actual	lipogenic	pathway),	which	might	even	
be	of	therapeutic	value	in	acne.
3.3 | NA exerts anti‐proliferative actions, but 
does not influence lipopolysaccharide (LPS)‐induced 
pro‐inflammatory response of the sebocytes
Considering	that	sebum	production	 is	realized	via	holocrine	secre‐
tion,	its	clinical	level	does	not	only	depend	on	the	lipid	production	of	
the	individual	sebocytes,	but	also	on	the	number	of	the	lipid	produc‐
ing	cells.2,3,37‐39	Thus,	a	potent	anti‐acne	agent	 is	also	expected	to	
F I G U R E  1  NA	does	not	influence	homeostatic	SLG,	but	normalizes	AA‐induced,	excessive,	acne‐mimicking	lipid	production.	(A‐B)	Nile	
Red	assay.	SLG	of	SZ95	sebocytes	was	assessed	following	48‐hr	treatments.	Results	are	expressed	in	the	percentage	of	the	vehicle	control	
(100%,	solid	line)	as	mean	±	SEM	of	four	independent	determinations.	Two	additional	experiments	yielded	similar	results.	*,	**	and	***	mark	
significant	(P	<	0.05,	0.01	and	0.001,	respectively)	differences,	as	indicated.	(C)	CyQUANT‐assay.	Sebocytes	were	plated	at	low	(2000/well)	
initial	cell	count	to	enable	rapid	proliferation.	Cell	count	was	assessed	following	72‐hr	treatments.	Results	are	expressed	in	the	percentage	of	
the	24‐hr	vehicle	control	(100%,	solid	line)	as	mean	±	SEM	of	four	independent	determinations.	Two	additional	experiments	yielded	similar	
results.	**	marks	significant	(P	<	0.01)	differences,	as	indicated.	AA,	arachidonic	acid;	NA,	nicotinic	acid
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suppress	proliferation	of	sebocytes.	In	order	to	enable	rapid	prolifer‐
ation,	SZ95	sebocytes	were	plated	at	low	initial	density	(2000	cells/
well),	and	treated	by	NA	(1‐100	μmol/L)	for	72	hours.	 Importantly,	
NA	 exerted	 a	 significant	 and	 concentration‐dependent	 anti‐prolif‐
erative	 effect,	 ie	 it	 suppressed	 cell	 growth	 compared	 to	 the	 daily	
vehicle	 control	 group,	 but	 unlike	 the	 lipostatic	 effects,	 anti‐prolif‐
erative	actions	only	developed	at	higher	(10‐100	μmol/L)	concentra‐
tions	(Figure	1C).	It	is	also	noteworthy	that	perfectly	in	line	with	the	
viability	data	 (Figure	S1‐S2),	 the	cell	count	did	not	decrease	below	
the	level	of	the	24‐hr	control,	arguing	for	the	onset	of	a	pure	anti‐
proliferative	action	without	any	detrimental	effects	on	the	viability.
Besides	 the	 pathologically	 elevated	 SLG,	 another	 important	
contributor	to	the	development	of	acne	is	inflammation1‐4;	thus,	we	
investigated	the	effects	of	NA	on	the	immune	behaviour	of	the	sebo‐
cytes.	Pro‐inflammatory	response	was	evoked	by	5	μg/ml	lipopoly‐
saccharide	(LPS)	according	to	our	previously	optimized	protocol.24,25 
As	expected,	3‐hr	LPS	treatment	was	able	to	induce	a	strong	up‐reg‐
ulation	of	various	pro‐inflammatory	cytokines	at	the	mRNA	level,	in‐
cluding	interleukin	(IL)‐1α,	IL‐1β,	IL‐6,	IL‐8 and tumour necrosis factor‐α 
(TNF‐α)	(Q‐PCR;	Figure	2A).	We	found	that	100	μmol/L	NA	did	not	
suppress	the	LPS‐induced	up‐regulation	of	the	above	cytokines,	and	
it	had	no	effect	when	it	was	administered	alone	either	(Figure	2A).	
In	order	to	get	a	deeper	insight	to	the	effects	of	NA	on	the	inflam‐
matory	 responses,	we	also	measured	 release	of	 IL‐6	and	 IL‐8,	 two	
key	cytokines,	which,	upon	being	secreted	by	the	sebocytes,	are	in‐
volved	in	the	regulation	of	Th17	polarization.
40	In	line	with	the	mRNA	
level	data,	ELISA	measurement	of	 the	supernatants	 following	3‐hr	
(to	assess	early	release	of	the	preformed	cytokine	pool)	and	24‐hr	
treatments	 (to	 observe	 release	 of	 de	 novo	 synthesized	 cytokines)	
did	 not	 reveal	 any	 NA‐mediated	 effects	 on	 the	 cytokine	 release	
(Figure	2B‐C).	Thus,	our	data	support	the	concept	that	NA	is	unlikely	
to	directly	influence	immune	behaviour	of	human	sebocytes.
3.4 | Lipostatic effects of NA are mediated via the 
activation of a Ca2+‐dependent signalling pathway
Next,	we	intended	to	unveil	the	mechanism	of	the	lipid	synthe‐
sis	reducing	activity.	Since	elevation	of	the	[Ca2+]IC	often	leads	
F I G U R E  2  NA	does	not	reduce	cytokine	expression	and	release	of	human	sebocytes.	(A)	Q‐PCR	IL‐1α,	IL‐1β,	IL‐6,	IL‐8 and TNF‐α	mRNA	
expressions	were	determined	following	3‐hr	LPS‐treatment	with	or	without	NA.	Data	are	presented	by	using	ΔΔCT	method	regarding	18S 
RNA‐normalized	mRNA	expressions	of	the	vehicle	control	as	1	(solid	line).	Data	are	expressed	as	mean	±	SEM	of	2‐3	determinations.	One	
additional	experiment	yielded	similar	results.	**	and	***P	<	0.01	and	0.001,	respectively,	as	indicated.	(B,	C)	ELISA.	IL‐6	and	IL‐8	content	
of	the	sebocyte	supernatants	was	determined	following	3‐hr	(B)	and	24‐hr	(C)	LPS‐treatment	with	or	without	NA.	Data	are	expressed	as	
mean	±	SEM	of	three	determinations.	One	additional	experiment	yielded	similar	results.	*,	**,	and	***	mark	significant	(P	<	0.05,	0.01	or	
0.001,	respectively)	differences	compared	to	the	vehicle	control.	LPS,	lipopolysaccharide;	NA,	nicotinic	acid
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to	lipostatic	actions	similar	to	the	ones	described	above,26,41‐43 
and	 it	 is	 well‐documented	 that	 administration	 of	 NA	 elevates	
[Ca2+]IC	 in	 certain	 cell	 types,
10,11	 we	 first	 asked	 if	 alterations	
of	 [Ca2+]IC	 play	 any	 role	 in	mediating	 lipostatic	 effects	 of	NA.	
Importantly,	we	found	that	lipostatic	effects	could	be	prevented	
by	 the	 co‐administration	 of	 the	 cell‐permeable	 Ca2+‐chelator	
BAPTA	AM	 (Figure	3A),	 indicating	 that,	 similar	 to	 eg	CBD,	NA	
also	 suppressed	 SLG	 via	 activating	 a	 Ca2+‐coupled	 signalling	
pathway.
3.5 | Lipostatic concentrations of NA increase 
[Ca2±]IC via activating surface membrane non‐TRPV 
Ca2± channels
Next,	 we	 found	 that	 potent	 lipostatic	 and	 anti‐proliferative	 con‐
centrations	 of	 NA	 were	 able	 to	 substantially	 and	 concentra‐
tion‐dependently	 increase	 [Ca2+]IC	 (Fluo‐4	 AM‐based	 fluorescent	
Ca2+‐measurement;	 Figure	 3B),	 most	 likely	 via	 activating	 plasma	
membrane	calcium	channels,	since	the	signal	was	almost	completely	
absent	in	nominally	calcium‐free	medium	(Figure	3C‐D).	Considering	
that	NA	was	shown	to	directly	activate	certain	calcium‐permeable	
transient	receptor	potential	ion	channels	belonging	to	the	vanilloid	
(TRPV)	subclass,44‐46	and	that	certain	TRPV	channels	were	demon‐
strated	to	suppress	SLG,26,42,43	we	probed	their	involvement	in	the	
onset	of	the	NA‐induced	calcium	signal	by	using	ruthenium	red	(RR),	
a	well‐known	pan‐antagonist	of	the	TRPV	channels.47	 Importantly,	
we	 found	 that	 RR	was	 unable	 to	modify	 the	NA‐induced	 calcium	
signals	 (Figure	3B‐C)	 indicating	that	they	are	 likely	to	be	mediated	
via	yet	unknown,	non‐TRPV	surface	membrane	calcium	permeable	
pores.
3.6 | Sebocytes express HCA2 receptor, which 
selectively mediates lipostatic and [Ca2±]IC‐increasing 
effects of NA
Since	the	above	functional	data	on	the	calcium	homeostasis	made	
the	 involvement	 of	 TRPV	 channels	 in	mediating	 lipostatic	 actions	
of	NA	highly	unlikely,	we	asked	if	the	major	NA	receptor,	 ie	HCA2,	
contributes	to	this	process.	Importantly,	we	found	that	HCA2	is	in‐
deed	 expressed	 by	 human	 sebocytes	 both	 at	 the	mRNA	 (Q‐PCR;	
Figure	4A)	and	protein	levels	(immunofluorescence;	Figure	4B).	Next,	
in	 the	 lack	 of	 potent	 and	 selective	 antagonists,14	 siRNA‐mediated	
selective	gene	silencing	was	applied,	which	resulted	in	a	significant	
decrease	 in	both	mRNA	 (Figure	5A)	 and	protein	 (Figure	5B‐C)	 ex‐
pression	of	HCA2.	Moreover,	as	revealed	by	Nile	Red	assays	simulta‐
neously	executed	on	non‐sense	RNA‐transfected	scrambled	control	
F I G U R E  3  Lipostatic	effects	of	NA	are	Ca2+‐dependent	ones,	
and	NA	increases	[Ca2+]IC	of	human	sebocytes	in	a	concentration‐
dependent	manner,	via	activating	surface	membrane	non‐TPRV	
Ca2+‐channels.	(A)	Nile	Red	assay.	SLG	of	SZ95	sebocytes	was	
assessed	following	48‐hr	treatments.	Results	are	expressed	
in	the	percentage	of	the	vehicle	control	(100%,	solid	line)	as	
mean	±	SEM	of	four	independent	determinations.	One	additional	
experiments	yielded	similar	results.	***	marks	significant	(P	<	0.001)	
difference,	as	indicated.	n.s.:	not	significant.	(B‐C)	Fluo‐4	AM‐
based	fluorescent	Ca2+‐measurement.	Compounds	were	applied	
as	indicated	by	the	arrows.	Fluorescence	(measured	in	relative	
fluorescence	units)	was	normalized	to	the	baseline.	“Low	[Ca2+]EC”	
indicates	the	use	of	nominally	Ca2+‐free	Hank's	solution.	One	
additional	experiment	yielded	similar	results.	(D)	Statistical	analysis	
of	the	peak	fluorescence	(F/F0)	values	shown	on	panel	(C).	Data	are	
presented	as	mean	±	SEM	of	N	=	12	independent	determinations.	
***P	<	0.001	compared	to	the	NA	treatment	in	normal	[Ca2+]EC.	NA:	
nicotinic	acid;	RR:	ruthenium	red	(pan‐TRPV	channel	blocker)
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as	well	as	HCA2‐silenced	sebocytes,	lipostatic	action	of	NA	was	se‐
lectively	mediated	via	activating	HCA2,	since	silencing	of	the	recep‐
tor	completely	abrogated	it	(Figure	5D).	Intriguingly,	HCA2‐silencing	
had	no	obvious	impact	on	AA‐induced	lipogenesis	(Figure	5D),	and	
neither	AA,	nor	NA	 treatment	 influenced	HCA2	 expression	of	un‐
transfected	sebocytes	(Figure	S4).	Last,	but	not	least,	we	could	also	
demonstrate	that	siRNA‐mediated	silencing	of	HCA2	prevented	the	
NA‐induced	transient	elevation	of	the	[Ca2+]IC	(Figure	5E),	support‐
ing	the	concept	that,	similar	to	eg	Langerhans	cells,10,11	it	was	cou‐
pled	to	HCA2‐activation	in	sebocytes	as	well.
4  | DISCUSSION
In	the	current	study	we	provide	evidence	that,	without	influencing	
basal,	 homeostatic	 lipid	 synthesis	 (Figure	 1A)	 or	 viability	 (Figures	
S1	and	S2)	of	human	sebocytes,	NA	normalizes	acne‐mimicking,	ex‐
cessive	SLG	induced	by	various	pro‐acne	agents	(Figure	1B;	Figure	
S3),	 and	 exerts	 concentration‐dependent	 anti‐proliferative	 effects	
(Figure	1C).	These	actions	are	realized	via	the	activation	of	a	previ‐
ously	unknown	regulator	of	the	sebocyte	biology,	the	HCA2	receptor	
(Figures	3‐5).	Thus,	our	data	not	only	highlight	the	possibility	of	der‐
matological	use	of	NA,	a	well‐characterized	lipid‐lowering	substance	
having	a	 long	clinical	history,	and	exhibiting	acceptable	side	effect	
and	safety	profiles,	but	also	introduce	a	previously	unknown,	attrac‐
tive	 and	 druggable	 pharmacological	 target	 (ie	 HCA2	 receptor)	 for	
future	sebostatic	and	anti‐acne	drug	development	(Figure	6).	Well‐
controlled	clinical	trials	by	using	appropriate	topical	formulations	de‐
livering	NA	directly	to	the	sebaceous	glands	are	therefore	urgently	
invited	to	exploit	the	therapeutic	potential	of	this	sebaceous	gland‐
wise	previously	completely	unexplored	regulatory	system.
Although	 to	 the	best	of	our	knowledge,	no	placebo‐controlled	
clinical	 trials	were	 organized	 so	 far	 to	 dissect	 the	 acne‐wise	 rele‐
vant	 dermatological	 effects	 of	 NA,	 beyond	 our	 above	 presented	
data,	 there	 are	 several	 pieces	 of	 evidence	 further	 supporting	 the	
concept	that	it	may	exert	beneficial	effects.	First,	in	pellagra	(ie	NA	
deficiency),	dyssebacia	can	often	be	detected.6	Second,	side	effects	
of	NA	administered	at	pharmacological	doses	 include	skin	dryness	
(https	://www.drugs.com/pro/niacin.html).	 Third,	 results	 of	 certain	
pilot	 clinical	 studies	 suggest	 that	 orally	 administered	 NA	 may	 be	
beneficial	against	acne.18‐20
It	should	also	be	noted	that	topically	applied	nicotinamide	(the	
other	member	of	the	vitamin	B3	complex)	was	found	to	efficiently	
reduce	 sebum	 production	 in	 a	 double‐blind,	 placebo‐controlled	
clinical	study,48	and	a	growing	body	of	evidence	points	to	its	effi‐
ciency	in	the	clinical	management	of	acne,49‐51	as	well	as	 in	other	
pathological	 skin	conditions.52,53	Although	 the	mechanism	of	nic‐
otinamide's	 anti‐acne	 actions	 is	 still	 only	 partially	 understood,53 
it	 is	well‐evidenced	that	it	does	not	activate	HCA2;
16,17	therefore,	
it	definitely	does	not	share	 the	above	described	 lipostatic	 signal‐
ling	pathway	of	NA.	However,	considering	that	NA	can	be	metab‐
olized	 to	nicotinamide	 in	vivo,54	 it	 can	be	postulated	 that	 clinical	
efficiency	of	topically	administered	NA	might	even	be	superior	to	
the	one	of	nicotinamide,	since	theoretically,	 it	could	 include	both	
HCA2‐dependent	 direct,	 and,	 following	 its	 conversion	 to	 nicotin‐
amide,	HCA2‐independent,	indirect	anti‐acne	effects.
As	mentioned	above,	despite	of	 its	 lipostatic	 and	anti‐prolif‐
erative	efficiency,	NA	was	unable	to	prevent	LPS‐induced	pro‐in‐
flammatory	response	of	the	sebocytes	(Figure	2).	It	is	noteworthy	
that,	in	light	of	our	previous	data	obtained	by	using	the	non‐psy‐
chotropic	 phytocannabinoid	 (‐)‐cannabidiol,	 the	 observed	 anti‐
inflammatory	 inefficiency	 of	 NA	 is	 not	 completely	 unexpected.	
Indeed,	(‐)‐cannabidiol	was	found	to	exert	lipostatic	and	anti‐pro‐
liferative	 actions	 through	 the	 activation	 of	 TRPV4	 ion	 channels	
and	the	subsequent	elevation	of	the	[Ca2+]IC.	Its	anti‐inflammatory	
actions,	however,	were	independent	of	the	impact	on	the	calcium	
homeostasis,	 and	were	mediated	by	an	adenosine	A2A	 receptor‐
dependent	manner.26	Moreover,	we	have	recently	demonstrated	
that	 activation	 of	 another	 Ca2+‐permeable	 ion	 channel	 (namely	
TRPV3)	 suppressed	 SLG,	 and	 enhanced	 expression	 and	 release	
of	several	pro‐inflammatory	cytokines.42	Thus,	it	is	not	surprising	
that	 NA	was	 efficient	 in	 normalizing	 the	 SLG	 via	 the	HCA2‐de‐
pendent	elevation	of	 the	 [Ca2+]IC,	 but	 failed	 to	prevent	 the	pro‐
inflammatory	 action	 of	 LPS.	 Importantly,	 however,	 NA	 can	 still	
be	 effective	 in	 alleviating	 the	 acne‐accompanying	 pathological	
inflammation.55‐58
F I G U R E  4  HCA2	receptor	is	expressed	in	cultured	human	sebocytes.	(A)	Q‐PCR.	Sebocytes	were	harvested	at	different	confluences.	
HCA2	expression	was	normalized	to	the	level	of	glyceraldehyde‐3‐phosphate dehydrogenase	(GAPDH)	of	the	same	sample,	and	are	expressed	
as	mean	±	SD	of	three	determinations.	(B)	Immunofluorescent	labelling.	HCA2	immunoreactivity	was	determined	by	immunofluorescence	
labelling	(Alexa‐Fluor®‐488,	green)	in	SZ95	sebocytes.	Nuclei	were	counterstained	by	DAPI	(blue).	NC:	negative	control.	Scale	bar:	20	μm
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Indeed,	as	discussed	above,	NA	appears	to	have	negligible	ef‐
fects	 on	 the	 immune	 behaviour	 of	 human	 sebocytes	 (Figure	 2),	
but	through	direct	actions	on	professional	immune	cells,	eg	mac‐
rophages,59,60	it	still	has	the	potential	to	exert	beneficial	effects	in	
acne.	Moreover,	sebocytes	were	shown	to	regulate	skin	immune	
processes	not	only	via	direct	cytokine,	chemokine	and	adipokine	
release,2,3,40,55,56,58	but	also	by	the	composition	of	the	produced	
sebum.4,57	 Thus,	 although	 the	 exact	 impact	 of	NA	on	 the	 quali‐
tative	lipidome	is	to	be	dissected	in	further	targeted	studies,	our	
data	on	the	potent	 lipostatic	effects	of	NA	support	 the	concept	
that	it	might	beneficially	influence	cutaneous	immune	homeosta‐
sis	when	normalizing	SLG.
One	key	remaining	question	 is	how	exactly	HCA2	activation	can	
lead	to	Ca2+‐signals	in	human	sebocytes.	Although	HCA2	is	a	Gi‐cou‐
pled	receptor,	it	is	not	unprecedented	that	its	activation	is	followed	by	
Ca2+‐influx.10,11	Identification	of	the	so	far	unknown	Ca2+	permeable	
pore(s)	promises	to	be	of	great	clinical	relevance,	since	 it/they	could	
also	be	targeted	in	the	future	anti‐seborrhea/anti‐acne	drug	develop‐
ment,	especially,	since	unlike	eg	TRPV3,42	its/their	activation	results	in	
pure	sebostatic	effects	without	triggering	up‐regulation	and	release	of	
pro‐inflammatory	cytokines	(Figure	6).	Taken	together,	NA,	most	likely	
together	with	other	HCA2	receptor	agonists,	might	exhibit	great	trans‐
lational	potential	in	the	management	of	acne	and	seborrhea.	Placebo‐
controlled	 clinical	 trials	 by	 using	 appropriate	 topical	 formulations	
F I G U R E  5  Silencing	of	HCA2	prevents	lipostatic	and	[Ca
2+]IC‐elevating	effects	of	NA.	(A)	Q‐PCR.	Sebocytes	were	harvested	on	post‐
transfection	Day	2.	HCA2	expression	was	first	normalized	to	the	level	of	18S RNA	of	the	same	sample,	and	then	relative	mRNA	expression	
was	normalized	to	the	one	of	the	SCR	control	group.	Data	are	expressed	as	mean	±	SD	of	three	determinations.	(B)	Immunofluorescent	
labelling.	HCA2	expression	(green)	was	assessed	on	post‐transfection	Day	3.	Nuclei	were	counterstained	with	DAPI	(blue).	Scale	bars:	20	μm. 
(C)	Image	analysis	of	the	immunofluorescent	labelling	on	post‐transfection	Day	3.	Following	appropriate	background	subtraction	(for	details,	
see	the	Materials	and	methods	section)	data	of	the	green	channel	were	expressed	in	the	percentage	of	the	SCR	control,	and	presented	as	
mean	±	SEM	of	N	=	93	cells	in	altogether	2‐4	visual	fields	from	at	least	two	coverslips	in	each	group.	***P	<	0.001.	AU:	arbitrary	units.	SCR:	
non‐sense	(scrambled)	RNA	construct‐transfected	cells.	(D)	SLG	assessed	by	Nile	Red	assay	on	SCR‐transfected	as	well	as	HCA2‐silenced	
sebocytes.	48‐hr	treatment	of	the	sebocytes	was	initiated	on	post‐transfection	Day	2.	Results	are	expressed	in	the	percentage	of	the	SCR	
vehicle	control	(100%,	solid	line)	as	mean	±	SEM	of	four	independent	determinations.	Two	additional	experiments	yielded	similar	results.	
(E)	Statistical	analysis	of	Fluo‐4	AM‐based	fluorescent	Ca2+‐measurement	performed	on	post‐transfection	Day	2.	Fluorescence	(measured	
in	relative	fluorescence	units)	was	normalized	to	the	baseline.	The	peak	fluorescence	(F/F0)	values	are	presented	as	mean	±	SEM	of	N	=	7	
independent	determinations.	One	additional	experiment	yielded	similar	results.	*,	**	and	***	mark	significant	(P	<	0.05,	0.01	and	0.001,	
respectively)	differences,	as	indicated.	AA:	arachidonic	acid;	HCA2	siRNA:	HCA2‐silenced	cells;	NA:	nicotinic	acid;	SCR:	non‐sense	RNA‐
transfected	scrambled	control	cells
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delivering	NA	directly	to	the	sebaceous	glands	and	thereby	minimizing	
unwanted	 side	effects	 are	 therefore	urgently	 invited	 to	 scrutinize	 if	
dermatological	use	of	NA	(and	other	HCA2	agonists)	as	topically	ad‐
ministered	agent	provides	valuable	clinical	benefit.
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